Author:
Conole Daniel,Keating Gillian M.
Publisher
Springer Science and Business Media LLC
Reference70 articles.
1. Westerman EM, Heijerman HGM, Frijlink HW. Dry powder inhalation versus wet nebulisation delivery of antibiotics in cystic fibrosis patients. Expert Opin Drug Deliv. 2007;4(2):91–4.
2. National Institute for Health and Care Excellence. Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis: technology appraisal guidance. 2013. http://publications.nice.org.uk/colistimethate-sodium-and-tobramycin-dry-powders-for-inhalation-for-treating-pseudomonas-lung-ta276/clinical-need-and-practice . Accessed 19 Nov 2013.
3. Devesa I, Fernández-Ballester G, Ferrer-Montiel A. Targeting protein-protein interactions to rescue Δf508-cftr: a novel corrector approach to treat cystic fibrosis. EMBO Mol Med. 2013;5(10):1462–4.
4. Farrell PM. The prevalence of cystic fibrosis in the European Union. J Cyst Fibros. 2008;7(5):450–3.
5. Govan JRW, Deretic V. Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microb Rev. 1996;60(3):539–74.
Cited by
39 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献